NORD ANGLIA ED Stock Price, News & Analysis

Orocidin (OTCQB: NORD) announced development of a cGMP-compliant manufacturing process for QR-01, a 37-amino-acid peptide intended as a potential treatment for aggressive periodontitis, in collaboration with Syngene on October 20, 2025.

Key technical outcomes include a tailored SPPS approach, crude peptide purity >50%, final purity >99%, single maximum impurity of 0.4% (total impurities 0.6%), and a reproducible cGMP process with an overall yield of 10%. The produced cGMP material enables initiation of a planned Phase IIA pilot efficacy study in humans.

Nordicus Partners Corporation (OTCQB: NORD) announced on October 3, 2025 the formation of a new company, NoviThera ApS, to research and develop a novel monoclonal antibody (MaB) therapy for psoriasis. The drug invention was made by Alteral Therapeutics in Denmark and NoviThera acquired the drug development. Allan Wehnert will serve as CEO of NoviThera. The program will develop a human‑rat model expressing endogenous pathological peptides and test the candidate in other relevant animal disease models. The release describes NoviThera’s objective to develop an MaB that may cure or prevent psoriasis.

Nordicus Partners Corporation (OTCQB: NORD), a financial consulting firm focused on Nordic-US life sciences market entry, has submitted an application to uplist its common stock from the OTCQB Market to the Nasdaq Capital Market.

The company, which completed two acquisitions last year and is advancing its drug development pipeline in periodontitis and oral leukoplakia, aims to enhance shareholder value through increased visibility, liquidity, and access to institutional investors. The stock will continue trading under the symbol NORD on OTCQB pending Nasdaq approval.

Nordicus Partners Corporation (OTCQB: NORD), a business accelerator focused on Nordic and U.S. life sciences companies, announced significant changes to its Board of Directors. The company expanded its board from three to five members, with Henrik Keller resigning and three new directors joining: Torben Jensen (major shareholder), Kim T. Mücke (accounting expert and future Audit Committee chairman), and Andrew J. Ritter (experienced pharma CEO).

The new appointments align with Nordicus's strategy to acquire majority stakes in Nordic and U.S.-based life sciences companies, bringing expertise in funding, accounting, and strategic relationships.

Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has received positive feedback from the Danish Medicine Agency (DKMA) regarding its lead drug candidate QR-02 for oral leukoplakia treatment. The feedback suggests a clear pathway toward First in Human trials, potentially without requiring animal studies.

The company has developed a proprietary mucoadhesive oral topical formulation featuring extended retention time of 12-24 hours in the oral cavity, compared to conventional formulations lasting only 15-20 minutes. QR-02 uses imiquimod as its active ingredient, which is already approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma. The treatment aims to cure and reduce dysplasia levels in oral leukoplakia patients.

The First in Human trial is expected to commence by the end of 2025.

Orocidin, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced positive efficacy results for its lead periodontitis treatment candidate, QR-01, in a preclinical study with dogs. The 13-day small efficacy study, conducted on beagle dogs with clinically confirmed periodontitis, showed consistent improvements across key clinical endpoints including:

• Gingival Index
• Plaque Index
• Overall periodontal Disease

The treatment was well-tolerated with no adverse side effects reported. The company plans to proceed with a human pilot efficacy study scheduled to begin by the end of 2025.

Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced a strategic partnership with Syngene International . The collaboration aims to advance GMP peptide development programs using cutting-edge technology and scalable solutions.

The partnership will focus on developing Orocidin's QR-01, leveraging Syngene's capabilities in efficient and scalable manufacturing with reduced lead times. Syngene's infrastructure will provide access to skilled scientists and state-of-the-art facilities, ensuring a robust and streamlined supply chain for future commercialization.

This strategic alliance aligns with Nordicus Partners' specialization in supporting Nordic and U.S. life sciences companies establishing themselves in the U.S. market.

Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.

The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.

Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.

QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.